Abbott discloses proposed settlement of infant formula shareholder derivative suit
Abbott disclosed that a federal court on April 10, 2026 preliminarily approved a proposed settlement of a consolidated shareholder derivative lawsuit against certain current and former directors and officers. The settlement centers on corporate governance commitments, and the defendants deny any wrongdoing; it takes effect only if the court grants final approval at a hearing on June 4, 2026.
Key points
- Court preliminarily approved the proposed settlement on April 10, 2026, and set a final settlement hearing for June 4, 2026.
- Abbott will maintain or adopt governance policies listed in Exhibit A to the settlement stipulation and will commit funds needed to implement them; no cash payment amount is stated.
- Lead Plaintiffs' Counsel may request attorneys' fees and expenses of not more than $15.85 million, subject to court approval.
- Shareholder objections and notices of intent to appear must be received by May 18, 2026.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 2:16 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 17, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.